MicroRNA‐204‐5p Deficiency within the vmPFC Region Contributes to Neuroinflammation and Behavioral Disorders via the JAK2/STAT3 Signaling Pathway in Rats
Advanced Science · 2025-03 · 12 (10)
DOI: 10.1002/advs.202403080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.01.2025. Verfasst von Xiao Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Mental Disorders, The Second Hospital of Shandong University, School of Basic Medical Sciences, Shandong University, Jinan, Shandon…. Hauptthemen laut MEDLINE: MicroRNAs, STAT3 Transcription Factor, Janus Kinase 2, Prefrontal Cortex. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Major depressive disorder (MDD) is usually considered associate with immune inflammation and synaptic injury within specific brain regions. However, the molecular mechanisms underlying the neural deterioration resulting in depression remain unclear. Here, it is found that miR‐204‐5p is markedly downregulated in the ventromedial prefrontal cortex (vmPFC) in a chronic unpredictable mild stress (CUMS) induce rat model of depression. Knockdown of miR‐204‐5p in the vmPFC of normal rats results in depression and anxiety‐like behaviors accompanied with the activation of microglia, elevated levels of pro‐inflammatory cytokines, and increased numbers of neural apoptotic cells, effects which appear to be mediated by activation of the JAK2/STAT3 signaling pathway. Electrophysiological recordings further demonstrate that knockdown of miR‐204‐5p induces abnormal excitability of pyramidal neurons. In contrast, upregulation of miR‐204‐5p in the vmPFC of CUMS rats significantly causes inhibition of JAK2/STAT3 signaling pathway, improvements in neuronal impairments, and an abolition of the depression and anxiety‐like behaviors. Moreover, pharmacological blocking of the JAK2/STAT3 signaling pathway significantly ameliorates abnormal behaviors resulting from miR‐204‐5p deficiency within the vmPFC. Collectively, these results provide robust evidence that the miR‐204‐5p/JAK2/STAT3 pathway may critically involve in the pathogenesis of depression, which may serve as potentially critical therapeutic target in the treatment of MDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Mental Disorders, The Second Hospital of Shandong University, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, 250012, China.
- Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.
- Department of Medical Psychology and Ethics, School of Basic Medical sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
ORCID-Profile: Shuyan Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, X., Gan, Y., Zhang, K., Wu, Y., Li, Y., Lan, T., Zhuang, X., Chen, S., & Yu, S. (2025). MicroRNA‐204‐5p Deficiency within the vmPFC Region Contributes to Neuroinflammation and Behavioral Disorders via the JAK2/STAT3 Signaling Pathway in Rats. Advanced Science, 12(10). https://doi.org/10.1002/advs.202403080
Vancouver
Chen X, Gan Y, Zhang K, Wu Y, Li Y, Lan T, et al. MicroRNA‐204‐5p Deficiency within the vmPFC Region Contributes to Neuroinflammation and Behavioral Disorders via the JAK2/STAT3 Signaling Pathway in Rats. Advanced Science. 2025;12(10). doi:10.1002/advs.202403080
BibTeX
@article{Chen2025,
author = {Chen, Xiao and Gan, Yeting and Zhang, Kaiqi and Wu, Yuhan and Li, Ye and Lan, Tian and Zhuang, Xianghua and Chen, Shihong and Yu, Shuyan},
title = {MicroRNA‐204‐5p Deficiency within the vmPFC Region Contributes to Neuroinflammation and Behavioral Disorders via the JAK2/STAT3 Signaling Pathway in Rats},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {10},
doi = {10.1002/advs.202403080}
}
EUVIMED